A-class prostaglandins: Early findings and new perspectives for overcoming tumor chemoresistance

Cancer Letters

Volumn 320, Issue 2, 2012, Pages 150-157

  Díez Dacal, Beatriz ^a   Pérez Sala, Dolores ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

AKR1B10; Chemoresistance; Cyclopentenone; GST

Indexed keywords

13,14 DIHYDRO 15 DEOXY DELTA7 PROSTAGLANDIN A1 METHYL ESTER; 15 HYDROXY 9 OXOPROSTA 7,10,13 TRIENOIC ACID; 3,4 DIHYDRO 2,8 DIISOPROPYL 3 THIOXO 2H 1,4 BENZOXAZINE 4 ACETIC ACID; 8 ISO PROSTAGLANDIN A1; 8 ISO PROSTAGLANDIN A2; ABC TRANSPORTER; AKR 1B10; ANTHRACYCLINE DERIVATIVE; CISPLATIN; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PROSTAGLANDIN A; PROSTAGLANDIN A1; PROSTAGLANDIN A2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MODIFICATION; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

EID: 84859625071     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.003     Document Type: Review

References (85)

1. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 2008, 65:3145-3167.
2. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J. Clin. Invest. 2011, 121:3797-3803.
3. Hamberg M., Samuelsson B. Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. J. Biol. Chem. 1966, 241:257-263.
4. Zusman R.M., Caldwell B.V., Speroff L., Behrman H.R. Radioimmunoassay of the A prostaglandins. Prostaglandins 1972, 2:41-53.
5. Ziboh V.A., Miller C.C., Cho Y. Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites. Am. J. Clin. Nutr. 2000, 71:361S-366S.
6. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
7. Bregman M.D., Funk C., Fukushima M. Inhibition of human melanoma growth by prostaglandin A, D, and J analogues. Cancer Res. 1986, 46:2740-2744.
8. Kato T., Fukushima M., Kurozumi S., Noyori R. Antitumor activity of delta 7-prostaglandin A1 and delta 12-prostaglandin J2 in vitro and in vivo. Cancer Res. 1986, 46:3538-3542.
9. Sasaki H., Niimi S., Akiyama M., Tanaka T., Hazato A., Kurozumi S., Fukushima S., Fukushima M. Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo. Cancer Res. 1999, 59:3919-3922.
10. Ishikawa T., Akimaru K., Nakanishi M., Tomokiyo K., Furuta K., Suzuki M., Noyori R. Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump). Biochem. J. 1998, 336:569-576.
11. Liu J.D., Lin S.Y., Ho Y.S., Pan S., Hung L.F., Tsai S.H., Lin J.K., Liang Y.C. Involvement of c-jun N-terminal kinase activation in 15-deoxy-delta12,14-prostaglandin J2-and prostaglandin A1-induced apoptosis in AGS gastric epithelial cells. Mol. Carcinog. 2003, 37:16-24.
12. Kikuchi Y., Kita T., Hirata J., Fukushima M. Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells. Cancer Metast. Rev. 1994, 13:309-315.
13. Honn K.V., Marnett L.J. Requirement of a reactive alpha, beta-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by "A" series prostaglandins. Biochem. Biophys. Res. Commun. 1985, 129:34-40.
14. Santoro M.G., Crisari A., Benedetto A., Amici C. Modulation of the growth of a human erythroleukemic cell line (K562) by prostaglandins: antiproliferative action of prostaglandin A. Cancer Res. 1986, 46:6073-6077.
15. Santoro M.G. Antiviral activity of cyclopentenone prostanoids. Trends Microbiol. 1997, 5:276-281.
16. Hayes M.M., Lane B.R., King S.R., Markovitz D.M., Coffey M.J. Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects. J. Biol. Chem. 2002, 277:16913-16919.
17. Amici C., Belardo G., Rossi A., Santoro M.G. Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J. Biol. Chem. 2001, 276:28759-28766.
18. Hirayama E., Hattori M., Kim J. Specific binding of heat shock protein 70 with HN-protein inhibits the HN-protein assembly in Sendai virus-infected Vero cells. Virus Res. 2006, 120:199-207.
19. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase. Nature 2000, 403:103-108.
20. Homem de Bittencourt P.I., Lagranha D.J., Maslinkiewicz A., Senna S.M., Tavares A.M., Baldissera L.P., Janner D.R., Peralta J.S., Bock P.M., Gutierrez L.L., Scola G., Heck T.G., Krause M.S., Cruz L.A., Abdalla D.S., Lagranha C.J., Lima T., Curi R. LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 2007, 193:245-258.
21. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., Brown M., Lazar M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 1995, 270:23975-23983.
22. 2. J. Biol. Chem. 2003, 278:51251-51260.
23. 1 allows assessment of PPAR-independent effects and identification of novel cellular targets for covalent modification. Chem. Biol. Interact. 2010, 183:212-221.
24. Fukushima M. Development of antineoplastic prostaglandins. Gan To Kagaku Ryoho 1983, 10:1930-1935.
25. Pérez-Sala D. Electrophilic eicosanoids: signaling and targets. Chem. Biol. Interact. 2011, 192:96-100.
26. Díez-Dacal B., Pérez-Sala D. Anti-inflammatory prostanoids: focus on the interactions between electrophile signalling and resolution of inflammation. ScientificWorldJournal 2010, 10:655-675.
27. Garzón B., Oeste C.L., Díez-Dacal B., Pérez-Sala D. Proteomic studies on protein modification by cyclopentenone prostaglandins: expanding our view on electrophile actions. J. Proteom. 2011, 74:2243-2263.
28. Tanaka H., Kitade M., Iwashima M., Iguchi K., Takahashi T. Effective irreversible alkylating reagents based on the structure of clavulones. Bioorg. Med. Chem. Lett. 2004, 14:837-840.
29. Fukushima S., Kishimoto S., Takeuchi Y., Fukushima M. Preparation and evaluation of o/w type emulsions containing antitumor prostaglandin. Adv. Drug Deliv. Rev. 2000, 45:65-75.
30. Wiley M.H., Feingold K.R., Grunfeld C., Quesney-Huneeus V., Wu J.M. Evidence for cAMP-independent inhibition of S-phase DNA synthesis by prostaglandins. J. Biol. Chem. 1983, 258:491-496.
31. Ishioka C., Kanamaru R., Sato T., Dei T., Konishi Y., Asamura M., Wakui A. Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60. Cancer Res. 1988, 48:2813-2818.
32. Bui T., Kuo C., Rotwein P., Straus D.S. Prostaglandin A2 specifically represses insulin-like growth factor-I gene expression in C6 rat glioma cells. Endocrinology 1997, 138:985-993.
33. Choi A.M., Fargnoli J., Carlson S.G., Holbrook N.J. Cell growth inhibition by prostaglandin A2 results in elevated expression of gadd153 mRNA. Exp. Cell Res. 1992, 199:85-89.
34. Gorospe M., Liu Y., Xu Q., Chrest F.J., Holbrook N.J. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol. Cell. Biol. 1996, 16:762-770.
35. Tanikawa M., Yamada K., Tominaga K., Morisaki H., Kaneko Y., Ikeda K., Suzuki M., Kiho T., Tomokiyo K., Furuta K., Noyori R., Nakanishi M. Potent prostaglandin A1 analogs that suppress tumor cell growth through induction of p21 and reduction of cyclin E. J. Biol. Chem. 1998, 273:18522-18527.
36. Joubert A., Bianchi P., Maritz C., Joubert F. Influence of prostaglandin A2 on Bax, Bcl-2 and PCNA expression in MCF-7 cells. Biomed. Res. 2006, 27:157-162.
37. Lee S.Y., Ahn J.H., Ko K.W., Kim J., Jeong S.W., Kim I.K., Kim J., Kim H.S. Prostaglandin A2 activates intrinsic apoptotic pathway by direct interaction with mitochondria in HL-60 cells. Prostagland. Other Lipid Mediat. 2010, 91:30-37.
38. 1 increases IkBalpha gene expression. FASEB J. 1998, 12:1371-1378.
39. 2 inhibition of NF-κB DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 2001, 276:35530-35536.
40. Stamatakis K., Pérez-Sala D. Prostanoids with cyclopentenone structure as tools for the characterization of electrophilic eicosanoid-protein interactomes. Ann. N.Y. Acad. Sci. 2006, 1091:548-570.
41. Amici C., Sistonen L., Santoro M.G., Morimoto R.I. Antiproliferative prostaglandins activate heat shock transcription factor. Proc. Natl. Acad. Sci. USA 1992, 89:6227-6231.
42. Pavithra L., Sreenath K., Singh S., Chattopadhyay S. Heat-shock protein 70 binds to a novel sequence in 5' UTR of tumor suppressor SMAR1 and regulates its mRNA stability upon prostaglandin A2 treatment. FEBS Lett. 2010, 584:1187-1192.
43. Suzuki M., Kiho T., Tomokiyo K., Furuta K., Fukushima S., Takeuchi Y., Nakanishi M., Noyori R. Rational design of antitumor prostaglandins with high biological stability. J. Med. Chem. 1998, 41:3084-3090.
44. Marini S., Palamara A.T., Garaci E., Santoro M.G. Growth inhibition of Friend erythroleukaemia cell tumours in vivo by a synthetic analogue of prostaglandin A: an action independent of natural killer-activity. Br. J. Cancer 1990, 61:394-399.
45. Milne G.L., Yin H., Hardy K.D., Davies S.S., Roberts L.J. Isoprostane generation and function. Chem. Rev. 2011, 111:5973-5996.
46. Levonen A.L., Landar A., Ramachandran A., Ceaser E.K., Dickinson D.A., Zanoni G., Morrow J.D., Darley-Usmar V.M. Cellular mechanisms of redox cell signaling: the role of cysteine modification in controlling antioxidant defenses in response to electrophilic lipid oxidation products. Biochem. J. 2004, 378:373-382.
47. Renedo M., Gayarre J., García-Domínguez C.A., Pérez-Rodríguez A., Prieto A., Cañada F.J., Rojas J.M., Pérez-Sala D. Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. Biochemistry 2007, 46:6607-6616.
48. 1: implications for anti-tumoral activity. Cancer Res. 2011, 71:4161-4171.
49. Chiang P.C., Kung F.L., Huang D.M., Li T.K., Fan J.R., Pan S.L., Shen Y.C., Guh J.H. Induction of Fas clustering and apoptosis by coral prostanoid in human hormone-resistant prostate cancer cells. Eur. J. Pharmacol. 2006, 542:22-30.
50. Shen Y.C., Lo K.L., Chang J.Y., Lin Y.S., Mendbayar K., Kuo Y.H., Lin Y.C. New cytotoxic prostanoids from Taiwanese soft coral Clavularia viridis. Chem. Biodivers. 2010, 7:2702-2708.
51. Kikuchi Y., Kita T., Miyauchi M., Hirata J., Sasa H., Nagata I., Fukushima M. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells. J. Cancer Res. Clin. Oncol. 1992, 118:453-457.
52. Sasaki H., Fukushima M. Prostaglandins in the treatment of cancer. Anticancer Drugs 1994, 5:131-138.
53. Gillet J.P., Gottesman M.M. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol. 2010, 596:47-76.
54. Kellner U., Sehested M., Jensen P.B., Gieseler F., Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 2002, 3:235-243.
55. Suzuki K., Shono F., Uyeda M. Inhibition of topoisomerases by antitumor prostaglandins. Biosci. Biotechnol. Biochem. 1998, 62:2073-2075.
56. Suzuki K., Uyeda M. Inhibitory properties of antitumor prostaglandins against topoisomerases. Biosci. Biotechnol. Biochem. 2002, 66:1706-1712.
57. Petrash J.M. All in the family: aldose reductase and closely related aldo-keto reductases. Cell. Mol. Life Sci. 2004, 61:737-749.
58. Yan R., Zu X., Ma J., Liu Z., Adeyanju M., Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int. J. Cancer 2007, 121:2301-2306.
59. Martin H.J., Breyer-Pfaff U., Wsol V., Venz S., Block S., Maser E. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 2006, 34:464-470.
60. Boller Y.C., Brandes L.M., Russell R.L., Lin Z.P., Patierno S.R., Kennedy K.A. Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol. Res. 2000, 12:383-395.
61. Ciucci A., Gianferretti P., Piva R., Guyot T., Snape T.J., Roberts S.M., Santoro M.G. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway. Mol. Pharmacol. 2006, 70:1812-1821.
62. Cagen L.M., Pisano J.J., Ketley J.N., Habig W.H., Jakoby W.B. The conjugation of prostaglandin A1 and glutathione catalyzed by homogeneous glutathione S-transferases from human and rat liver. Biochim. Biophys. Acta 1975, 398:205-208.
63. van Iersel M.L., Cnubben N.H., Smink N., Koeman J.H., van Bladeren P.J. Interactions of prostaglandin A2 with the glutathione-mediated biotransformation system. Biochem. Pharmacol. 1999, 57:1383-1390.
64. Evers R., Cnubben N.H., Wijnholds J., van Deemter L., van Bladeren P.J., Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 1997, 419:112-116.
65. Bickley J.F., Ciucci A., Evans P., Roberts S.M., Ross N., Santoro G.M. Reactions of some cyclopentenones with selected cysteine derivatives and biological activities of the product thioethers. Bioorg. Med. Chem. 2004, 12:3221-3227.
66. Noyori R., Suzuki M. Organic synthesis of prostaglandins: advancing biology. Science 1993, 259:44-45.
67. 1 methyl esters with thiols. J. Am. Chem. Soc. 1997, 119:2376-2385.
68. 2: role of glutathione. FEBS Lett. 2005, 579:5803-5808.
69. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., Glass C.K. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. USA 2000, 97:4844-4849.
70. Klatt P., Lamas S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem. 2000, 267:4928-4944.
71. J. Gayarre, M.I. Avellano, F.J. Sánchez-Gómez, M.J. Carrasco, F.J. Cañada, D. Pérez-Sala, Modification of proteins by cyclopentenone prostaglandins is differentially modulated by GSH in vitro, Ann. N.Y. Acad. Sci. 1096 (2007) 78-85.
72. Sánchez-Gómez F.J., Díez-Dacal B., Pajares M.A., Llorca O., Pérez-Sala D. Cyclopentenone prostaglandins with dienone structure promote cross-linking of the chemoresistance-inducing enzyme glutathione transferase P1-1. Mol. Pharmacol. 2010, 78:723-733.
73. Sánchez-Gómez F.J., Gayarre J., Avellano M.I., Pérez-Sala D. Direct evidence for the covalent modification of glutathione-S-transferase P1-1 by electrophilic prostaglandins: implications for enzyme inactivation and cell survival. Arch. Biochem. Biophys. 2007, 457:150-159.
74. Kobayashi M., Li L., Iwamoto N., Nakajima-Takagi Y., Kaneko H., Nakayama Y., Eguchi M., Wada Y., Kumagai Y., Yamamoto M. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol. Cell. Biol. 2009, 29:493-502.
75. Baird L., Dinkova-Kostova A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85:241-272.
76. Levonen A.L., Dickinson D.A., Moellering D.R., Mulcahy R.T., Forman H.J., Darley-Usmar V.M. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1846-1851.
77. Shibata T., Yamada T., Ishii T., Kumazawa S., Nakamura H., Masutani H., Yodoi J., Uchida K. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J. Biol. Chem. 2003, 278:26046-26054.
78. Cassidy P., Edes K., Nelson C., Parsawar K., Fitzpatrick F., Moos P. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 2006, 27:2538-2549.
79. Lalier L., Cartron P.F., Olivier C., Loge C., Bougras G., Robert J.M., Oliver L., Vallette F.M. Prostaglandins antagonistically control Bax activation during apoptosis. Cell Death Differ. 2011, 18:528-537.
80. Su F., Hu X., Jia W., Gong C., Song E., Hamar P. Glutathione S transferase pi indicates chemotherapy resistance in breast cancer. J. Surg. Res. 2003, 113:102-108.
81. 1: focus on vimentin. J. Mass Spectrom. 2007, 42:1474-1484.
82. Kim W.J., Kim J.H., Jang S.K. Anti-inflammatory lipid mediator 15d-PGJ2 inhibits translation through inactivation of eIF4A. EMBO J. 2007, 26:5020-5032.
83. Covey T.M., Edes K., Coombs G.S., Virshup D.M., Fitzpatrick F.A. Alkylation of the tumor suppressor PTEN activates Akt and beta-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS One 2010, 5:e13545.
84. Zhang D.D. The Nrf2-Keap1-ARE signaling pathway: the regulation and dual function of Nrf2 in cancer. Antioxid. Redox Signal. 2010, 13:1623-1626.
85. Nishinaka T., Miura T., Okumura M., Nakao F., Nakamura H., Terada T. Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2. Chem. Biol. Interact. 2011, 191:185-191.